Evidence map›Paper›PMID 26444783›Full record

ArticleJournal of Alzheimer's disease : JAD2016

Age and its association with low insulin and high amyloid-β peptides in blood.

Huajie Li, Haihao Zhu, Max Wallack, Mkaya Mwamburi, Samer O Abdul-Hay, Malcolm A Leissring, Wei Qiao Qiu

Abstract read
In one paragraph

Article in Journal of Alzheimer's disease : JAD, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
0.9field-weighted citation impact, top 24% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it, 14 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 3 institutions in 2 countries.

Huajie LiDepartments of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Haihao ZhuDepartments of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Max WallackDepartments of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Mkaya MwamburiDepartment of Public Health and Family Medicine, Tufts University, Boston, MA, USA.
Samer O Abdul-HayDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.
Malcolm A LeissringDepartment of Neuroscience, Mayo Clinic Florida, Jacksonville, FL, USA.
Wei Qiao QiuDepartments of Pharmacology & Experimental Therapeutics, Boston University School of Medicine, Boston, MA, USA.
Boston University · USMayo Clinic in Florida · USTufts University · US

Funding

Plasma Amylin Impact on Cognitive Function and Brain Morphology in the Framingham Heart StudyR01AG049899 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI AU, RHODA, QIU, WEI QIAO WENDY · 2015 to 2019
$2.3M
Midcareer Investigator Award in Amylin, Cognition, and Alzheimer's DiseaseK24AG050842 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI QIU, WEI QIAO WENDY · 2015 to 2019
$850k
Insulin, Cognitive Impairment and Alzheimer's DiseaseK23AG022476 · NIA · TUFTS MEDICAL CENTER · PI QIU, WEI QIAO WENDY · 2003 to 2007
$658k
Amylin as a Diagnostic Test and Potential Treatment for Alzheimers DiseaseR21AG045757 · NIA · BOSTON UNIVERSITY MEDICAL CAMPUS · PI QIU, WEI QIAO WENDY · 2014 to 2015
$444k
NIA NIH HHS AG-022476NIA NIH HHS K23 AG022476NIA NIH HHS K24 AG050842NIA NIH HHS R01 AG049899NIA NIH HHS R21 AG045757
6 · The paper itself

Abstract

Age is the major risk factor for developing Alzheimer's disease (AD), and modifying age-related factors may help to delay the onset of the disease. The goal of this study was to investigate the relationship between age and the metabolic factors related to the risk of developing AD. The concentrations of insulin, amylin, and amyloid-β peptide (Aβ) in plasma were measured. We further measured the activity of serum Aβ degradation by using fluorescein- and biotin-labeled Aβ40. Apolipoprotein E4 allele (ApoE4) and cognitive impairment were characterized. Subjects were divided into three age groups: 60-70, 70-80, and ≥80 years old. We found that the older the subjects, the lower the concentration of insulin (p = 0.001) and the higher the concentration of Aβ1-40 (p = 0.004) in plasma. However, age was not associated with the concentration of another pancreatic peptide, amylin, and only marginally with Aβ1-42. These relationships remained in the absence of diabetes, cardiovascular disease, and stroke, and regardless of the presence of ApoE4 and cognitive impairment. Both age and ApoE4 were inversely associated with, while insulin was positively associated with, the activities of Aβ degradation in serum. Our study suggested that low concentration of insulin and high concentration of Aβ40 are aging factors related to the risk of AD.

Indexed as

AgingAgedAged, 80 and overAge DistributionAlzheimer DiseaseAmyloid beta-PeptidesApolipoprotein E4BiomarkersCognition DisordersCross-Sectional StudiesFemaleHumansInsulinIslet Amyloid PolypeptideLinear ModelsMaleAmyloid beta-Peptidesamyloid beta-protein (1-40)Apolipoprotein E4BiomarkersInsulinIslet Amyloid PolypeptidePeptide FragmentsageAlzheimer’s diseaseApoE4AβAβ degradationinsulin

Identifiers

PMID26444783
PMCPMC4835689
OpenAlexW2195569992

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.